These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27988971)

  • 1. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
    Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
    Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Immunoglobulins Alone for the Desensitization of Lung Transplant Recipients with Preformed Donor Specific Antibodies and Negative Flow Cytometry Crossmatch.
    Abdulqawi R; Alawwami M; Aldosari O; Aldosari Z; Alhuqbani M; Saleh RA; Esendagli D; Aldakhil H; De Vol EB; Alkattan K; Marquez KAH; Saleh W; Sandoqa S; Al-Mutairy EA
    Clin Transplant; 2024 Jul; 38(7):e15374. PubMed ID: 38979724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
    Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation.
    Hulbert AL; Pavlisko EN; Palmer SM
    Curr Opin Organ Transplant; 2018 Jun; 23(3):308-315. PubMed ID: 29742565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics.
    Roux A; Bendib Le Lan I; Holifanjaniaina S; Thomas KA; Hamid AM; Picard C; Grenet D; De Miranda S; Douvry B; Beaumont-Azuar L; Sage E; Devaquet J; Cuquemelle E; Le Guen M; Spreafico R; Suberbielle-Boissel C; Stern M; Parquin F;
    Am J Transplant; 2016 Apr; 16(4):1216-28. PubMed ID: 26845386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.
    Jackups R; Canter C; Sweet SC; Mohanakumar T; Morris GP
    J Clin Apher; 2013 Aug; 28(4):301-8. PubMed ID: 23426730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
    Slatinska J; Slavcev A; Honsova E; Hruba P; Kratochvilova I; Rohal T; Viklicky O
    HLA; 2018 Dec; 92 Suppl 2():47-50. PubMed ID: 30168284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
    Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk.
    Coutance G; d'Orio V; Belin L; Bréchot N; Saheb S; Lebreton G; Bouglé A; Rouvier P; Gautreau C; Ouldammar S; Chamillard X; Huot M; Amour J; Combes A; Leprince P; Varnous S
    Transplantation; 2019 Jul; 103(7):1439-1449. PubMed ID: 30376551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
    Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
    Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation.
    Yamanashi K; Chen-Yoshikawa TF; Hamaji M; Yurugi K; Tanaka S; Yutaka Y; Yamada Y; Nakajima D; Ohsumi A; Date H
    Gen Thorac Cardiovasc Surg; 2020 Feb; 68(2):142-149. PubMed ID: 31435872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.